Cambiogenplasmid
| Gene therapy | |
|---|---|
| Target gene | delivers new VEGF |
| Clinical data | |
| Trade names | Neovasculgen |
| Other names | Pl-VEGF165 |
| Routes of administration | Intraneural injection |
| ATC code | |
| Identifiers | |
| ChemSpider |
|
Neovasculgen is a gene-therapy drug for treatment of peripheral artery disease, including critical limb ischemia; it delivers the gene encoding for vascular endothelial growth factor (VEGF).[1][2] Neovasculogen is a plasmid encoding the CMV promoter and the 165 amino acid form of VEGF.[3][4] It was developed by the Human Stem Cells Institute in Russia and approved in Russia in 2011.
References
- ^ AdisInsight Vascular endothelial growth factor gene therapy - HSCI Page accessed 5 June 2016
- ^ "Gene Therapy for PAD Approved". 6 December 2011. Retrieved 5 August 2015.
- ^ Eurolab. Neovasculogen listing in Eurolab Page accessed 4 August 2015
- ^ Deev, R.; Bozo, I.; Mzhavanadze, N.; Voronov, D.; Gavrilenko, A.; Chervyakov, Yu.; Staroverov, I.; Kalinin, R.; Shvalb, P.; Isaev, A. (13 March 2015). "pCMV-vegf165 Intramuscular Gene Transfer is an Effective Method of Treatment for Patients With Chronic Lower Limb Ischemia". Journal of cardiovascular pharmacology and therapeutics. 20 (5): 473–82. doi:10.1177/1074248415574336. PMID 25770117.
See also
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |